医学
中止
抗甲状腺药物
格雷夫斯病
儿科
抗甲状腺药
疾病
甲状腺
甲巯咪唑
甲状腺功能
内科学
出处
期刊:Thyroid
[Mary Ann Liebert]
日期:2020-04-07
卷期号:30 (10): 1451-1457
被引量:26
标识
DOI:10.1089/thy.2019.0814
摘要
Background: None of the current therapeutic approaches for management of Graves' disease has been able to re-establish normal thyroid function in all patients. Objective: To describe the author's 35 years of personal experience in the management of Graves' hyperthyroidism and, in doing so, review current articles published on the long-term medical treatment of hyperthyroidism. Methods: All published articles related to ≥4 years of continuous antithyroid drug (ATD) treatment were searched. Findings were added and compared with studies published by the authors on the same topic. Results: Long-term ATD treatment is effective and safe, both in children and adults, for treatment of hyperthyroidism. Treatment of Graves' patients with ATDs >60 months causes euthyroidism up to 4 years after discontinuation of ATDs in the majority of patients. Long-term ATD therapy is not inferior to radioiodine therapy and may sometimes even be superior in some aspects, when considering serum lipid profile, cardiac function, mood, and cognition. Conclusions: Long-term ATD therapy for Graves' hyperthyroidism is efficient and safe and induces control of hyperthyroidism, without rendering the patient hypothyroid in the majority of patients.
科研通智能强力驱动
Strongly Powered by AbleSci AI